PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0851-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

RAPE TATE for form 1449A/PTO

DEC 2 2 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known				
Application Number	10/083,168			
Filing Date	February 26, 2002			
. First Named Inventor	Chen W. Liaw			
Art Unit	1646			
Examiner Name	Basi, Nirmal Singh			
Attorney Docket Number	23.US10.CIP			

			U.S. PATENT	OCUMENTS	
£	Cita	Document Number	Publication Date	Name of Patentee or Applicant of	Pages, Columns, Lines, Where Relevant
Examiner Initials	Cite No.'	Number - Kind Code ² (if known)	MM-DD-YYYY	Cited Document	Passages or Relevant Figures Appear
NW	A1	US-6,159,705	12/12/2000	Truehart et al	
		US-			
		US-			
		US-	•		
		US-			
]	US-			
		US-			

	FOREIGN PATENT DOCUMENTS						
Examiner Cite No.'		Foreign Patent Document		Name of Patentee or	Pages, Columns, Lines,		
	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	τ°		
			. :		·		
	ĺ			,			

	<u></u>			
Examiner Signature	VSn	Date Considered	6130/0	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www uspto gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Linder the Preservork Reduction Act of

PTO/SB/08b(05-03)
Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 10/083,168
Filing Date February 26, 2002
First Named Inventor Chen W. Liaw
Group Art Unit 1646
Examiner Name Basi, Nirmal Singh
Attorney Docket Number 23.US10.CIP

(use as many sheets as necessary)

Sheet 2 of 2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of Cite T² Examiner the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No. Initials number(s), publisher, city and/or country where published. Bao, et al., Database SwissProt, Acc. No. P25089, May 1, 1992, Alignment for SEQ ID NO 2. M A2 Bao, et al, Database PIR 73, Acc. No. C42009, September 30, 1993, Alignment for SEQ ID NO 3. А3 Durstin, et al., EMBL Database, Acc No. AC005946, November 8, 1994, Alignment for SEQ ID NO 1. Lamerdin, et al., EMBL Database, Acc. No. AC005946, November 7, 1998, Alignment for SEQ ID NO 1. Α5 Lamerdin, et al., EMBL Database, Acc No. AC06272, January 4, 1999, Alignment for SEQ ID NO 1. A6

Examiner Signature Nrh. R	Date Considered 5/Jo/or
---------------------------	-------------------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



The waster of

COPY OF PAPERS ORIGINALEY FILED

ģ

10 m

MU 2 9 2002 M

RECEIVED JUN 0 5 2002 TECH CENTER 1600/2000 200

<u></u>	The state of the s	HOEMARTON	LUT CENTER 1899/1909 f 18				
Fo	rm PTO-1449 Modified	Docket No. AREN-0320	Serial No. 10/083,168				
	st of Patent and Publications Cited by Applicant se several sheets if necessary)	Applicant Chen W. Liaw et al.					
	S. Department of Commerce atent and Trademark Office	Filing Date February 26, 2002	Group 1646				
OT	HER DOCUMENTS (Including Auth	or, Title, Date, Pertine	nt Pages, Etc.)				
Ner A	A Alla, S.A. et al., "Extracellular dom ligand binding and agonist sensing 1996, 271, 1748-1755	ains of the bradykinin B defined by anti-peptide a	2 receptor involved in antibodies," J. Biol. Chem.,				
Al	Advenier, C. et al., "Effects on the i and selective nonpeptide antagonist Respir. Dis., 1992, 146(5, Pt. 1), 11	of the neurokinin A (NI	of SR 48968, a potent (2) receptors," Am. Rev.				
AC	AC Alexander, W.S. et al., "Point mutations within the dimer interfact homology doma of c-Mpl induce constitutive receptor activity and tumorigenicity," <i>EMBO J.</i> , 1995, 14(22), 5569-5578						
AI	Arvanitikis, L. et al., "Human herpe protein-coupled receptor linked to co	svirus KSHV encodes a ell proliferation," Nature	constitutively active G-				
AE	Barker, E.L. et al., "Constitutively a novel inverse agonist activity of rece 11687-11690	ctive 5-hydroxytryptami eptor ligands," J. Biol. C	ne _{2C} receptors reveal hem., 1994, 269(16),				
AF	Baxter, G., "5-HT ₂ receptors: a famil 105-110	ly re-united?" Trends Ph	armacol. Sci., 1995, 16,				
AG	Besmer, P. et al., "A new acute trans oncogene v-kit with the protein kinas	forming feline retrovirus se gene family," <i>Nature</i> ,	s and relationship of its 1986, 320, 415				
AH	AH Blin, N. et al., "Mapping of single amino acid residues required for selective activation of G _{q/11} by the m3 muscarinic acetylcholine receptor," J. Biol. Chem., 1995, 270, 17741-17748						
AI	Bond, R.A. et al., "Inverse agonists a Based Drug Design, Leff, P. (ed.), N	Bond, R.A. et al., "Inverse agonists and G-protein-coupled receptors," in Receptor-Based Drug Design, Leff, P. (ed.), New York, M. Dekker, 1998, 363-377					
AJ	Boone, C. et al., "Mutations that alter the third cytoplasmic loop of the a-factor receptor lead to a constitutive and hypersensitive phenotype," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90(21), 9921-9925						
EXAMINER	Din Sm	DATE CONSIDERE	D 6730/08				

MAY 2 9 2002

RECEIVED

JUN 0 5 2002

TECH CENTER 160@29802 of 18

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

BAD Bocket No. **AREN-0320**

Serial No. 10/083,168

Applicant

Chen W. Liaw et al.

Filing Date

Group

February 26, 2002

1646

1	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	15-15	AK	Burstein, E.S. et al., "Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains," <i>Biochem. Pharmacol.</i> , 1996, 51(4), 539-544					
/	AL Burstein, E.S. et al., "Amino acid side chains that define muscarinic receptor/G-protein coupling. Studies of the third intracellular loop," J. Biol. Chem., 1996, 27 2882-2885							
		AM	Burstein, E.S. et al., "Constitutive act G _q ," FEBS Lett., 1995, 363(3), 261-2	ivation of muscarinic receptors by the G-protein 63				
		AN	Bylund, D., "International union of p. Pharmacol. Rev., 1994, 46, 121-136	harmacology nomenclature of adrenoceptors,"				
		AO	Casey, C. et al., "Constitutively active mutant 5-HT _{2A} serotonin receptors: inverse agonis activity of classical 5HT _{2A} antagonists," Soc. Neurosci., 1996, Abstract #699.10					
		AP	Cheatham, B. et al., "Substitution of the <i>erbB-2</i> oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin-receptor substrate 1," <i>Proc. Natl. Acad. Sci. USA</i> , 1993, 90, 7336-7340					
		AQ	Chen, J. et al., "Tethered Ligand Libration, 1995, 270, 23398-23401	Chen, J. et al., "Tethered Ligand Library for Discovery of Peptide Agonists," J. Biol. Chem., 1995, 270, 23398-23401				
		AR	Chen, T.S. et al., "Microbial hydroxylation and glucuronidation of the angiotensin II (AII) receptor antagonist MK 954," J. Antibiot. (Tokyo), 1993, 46(1), 131-134					
		AS	Chen, W. et al., "A colorimetric assay for measuring activation of G _s - and G _q -coupled signaling pathways," Anal. Biochem., 1995, 226(2), 349-354					
		AT	Chidiac, P. et al., "Inverse agonist activity of β-adrenergic antagonists," J. Pharm. Exp. Ther., 1994, 45, 490-499					
	AU Clozel, M. et al., " In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology," J. Cardiovas. Pharmacol., 1993, 22(Suppl. 8), S377-S379							
	EXAMINE	R	Unn	DATE CONSIDERED 6/3965				

۶ ۲

ž

MAY 2 9 2002

RECEIVED

JUN 0 5 2002

TECH CENTER-1600/290018

Form PTO-1449

Applicant

Serial No. 10/083,168

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

Chen W. Liaw et al.

Filing Date

U.S. Department of Commerce

	Patent and Trademark Office February 26, 2002 Group 1646						
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
AV Collesi, C. et al., "A splicing variant of the RON transcript induckinase activity and an invasive phenotype," Mol. Cell. Biol., 199							
	AW	Cooper, C.S. et al., "Molecular clonistransformed human cell line," Nature		ng gene from a chemically			
	AX	De Dios, I. et al., "Effect of L-364,71 Pancreatic Secretion of Hydrocortiso					
	AY	AY Desbios-Mouthon, C. et al., "Deletion of Asn ²⁸¹ in the α-subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization," J. Clin. Endocrinol. Metab., 1996, 81(2), 719-727					
	AZ	Di Renzo, M.F. et al., "Expression of human tissues," Oncogene, 1991, 6(1)	-	in normal and neoplastic			
	BA Di Renzo, M.F. et al., "Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas," Oncogene, 1992, 7, 2549-2553						
	BB	BB Duprez, L. et al., "Germline mutations of the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperethyroidism," Nature Genetics, 1994, 7, 396-401					
	BC	Eggericksx, D. et al., "Molecular Clo that Constitutively Activates Adenyla	-	• •			
	BD	Evans, B.E. et al., "Orally Active, Nonpeptide Oxytocin Antagonists," J. Med. Chem., 1992, 35, 3919-3927					
	BE	Fu, M. et al., "Functional autoimmune epitope on α ₁ -adrenergic receptors in patients with malignant hypertension," <i>Lancet</i> , 1994, 344, 1660-1663					
	BF	Furitsu, T. et al., "Identification of Mutations in the Coding Sequence of the Proto- oncogene c-kit in a Human Mast Cell Leukemia Cell Line Causing Ligand- independent Activation of c-kit Product," J. Clin. Invest., 1993, 92, 1736-1744					
	Gellai, M. et al., "Nonpeptide Endothelin Receptor Antagonists V: Prevention and Reversal of Acute Renal Failure in the Rat by SB 209670," J. Pharm. Exp. Therap., 1995, 275(1), 200-206						
EXAM	INER	Usaf M	DATE CONSIDER	ED 6/50/05			


Ä

1

- Ashrianica

Š.

ġ



TECH CENTER 1	fallenten of 18
---------------	-----------------

		MIN 2 STATE OF MAN 2 OF		JUN 0 5 2002		
		MAY 2 8 THE MAY 2 9 2	A TE	CH CENTER 168hpmmof 18		
	Form	PTO-144 Modified	Docket No.	Serial No.		
		ADE	AREN-0320	10/083,168		
	List of Patent and Publications Cited by Applicant Chen W. Liaw et al.					
		everal sheets if necessary)	Cucu W. Diaw et al.			
		Department of Commerce at and Trademark Office	Filing Date February 26, 2002	Group 1646		
	OTHE	CR DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)		
pso	вн	Gitter, B. et al., "Pharmacological Ch Selective Nonpeptide Substance P (N Exp. Therp., 1995, 275(2), 737-744				
	BI Gouilleux-Gruart, V. et al., "STAT-Related Transcription Factors are Constitutively Activated in Peripheral Blood Cells from Acute Leukemia Patients," <i>Blood</i> , 1996, 87(5), 1692-1697					
	BJ	Hansson, J.H. et al., "Hypertension consults genetic heterogeneity of Lid				
	BK Hasegawa, H. et al., "Two Isoforms of the Prostaglandin E Receptor EP3 Subtypes Different in Agonist-independent Constitutive Activity," J. Biol. Chem., 1996, 27 1857-1860					
	BL Hendler, F. et al., "Human Squamous Cell Lung Cancers Express Increased Epide Growth Factor Receptors," J. Clin. Invest., 1984, 74, 647-651					
	ВМ	Herrick-Davis, K. et al., "Constitutive by Site-Directed Mutagenesis," Soc.				
	BN Hieble, J., "International union of pharmacology. X. Recommendation for nomenclature of 1-adrenoceptors," <i>Pharm. Rev.</i> , 1995, 47, 267-270					
	BO Hill, S., "Distribution, Properties, and Functional Characteristics of Three Classes of Histamine Receptor," Am. Soc. Pharm. Exp. Therap., 1990, 42(1), 45-83					
	BP Högger, P. et al., "Activating and Inactivating Mutations in – and C-terminal i3 Loo Junctions of Muscarinic Acetylcholine Hm1 Receptors," J. Biol. Chem., 1995, 270(13), 7405-7410					
	BQ Ikeda, H. et al., "Expression and Functional Role of the Proto-oncogene c-kit in A Myeloblastic Leukemia Cells," Blood, 1991, 78(11), 2962-2968					
	BR Imura, R. et al., "Inhibition by HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist microbial origin, of atrial natriuretic peptide-induced relaxation of isolated rabbit aorta through the blockade of guanylyl cyclase-linked receptors," Mol. Pharm., 1992, 42, 982-990					

DATE CONSIDERED 6/3/65

COPY OF PAPERS ORIGINALLY FILED

4

÷.

EXAMINER

હ્યુ

Sandada. Addition

1.5. S. 3.14.

COPY OF PAPERS

Å

1.45.67

×

RECEIVED

•		MAY 2 8 202 11	May 2,8 20		JUN 0 5 2002	
	Form	Production Production	DADEMARK	Bocket No.	TECH CENTER 1640/2000 Serial No.	
	List of	f Patent and Publications		AREN-0320	10/083,168	
	(Cited by Applicant everal sheets if necessary)	J	Applicant Chen W. Liaw et al	•	
		Pepartment of Commerce t and Trademark Office		Filing Date February 26, 2002	Group 1646	
	OTHE	R DOCUMENTS (Inclu	iding Autho	or, Title, Date, Pertin	ent Pages, Etc.)	
Jakubik, J. et al., "Constitutive activity of the M ₁ -M ₄ subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists," FEBS Letts., 1995, 377, 275-279						
. [ВТ	Kjelsberg, M.A. et al., 'amino acid substitution	"Constitutive s at a single	e activation of the α _{1B} - site," J. Biol. Chem., 1	adrenergic receptor by all 1992, 267(3), 1430-1433	
	BU	Knapp, R. et al., "Molect FASEB J., 1995, 9, 516	cular biolog -525	y and pharmacology o	f cloned opioid receptors,"	
	BV Kosugi, S. et al., "Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty," Human Mol. Genetics, 1995, 4(2), 183-188					
	BW	Kosugi, S. et al., "Identification of Thyroid-Stimulating Antibody-Specific Interaction Sites in the N-Terminal Region of the Thyrotropin Receptor," <i>Mol. Endocrinology</i> , 1993, 7, 114-130				
	ВХ					
	BY Kudlacz, E. et al., "In Vitro and In Vivo Characterization of MDL 105,212A, a Nonpeptide NK-1/NK-2 Tachykinin Receptor Antagonist," J. Pharm. Exp. Therap., 1996, 277(2), 840-851					
	BZ Kuriu, A. et al., "Proliferation of Human Myeloid Leukemia Cell Line Associated with the Tyrosine-Phosphorylation and Activation of the Proto-oncogene c-kit Product," Blood, 1991, 78(11), 2834-2840					
·	CA Labbé-Jullié, C. et al., "Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotension binding and contractile responses in guinea pig ileum and colon," J. Pharm. Exp. Therap., 1994, 271(1), 267-276					
CB Latronico, A. et al., "A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty," J. Clin. Endocrinol. Metabl., 1995, 80(8), 2490-2494						
XAMINE	R	N s mc/h		DATE CONSIDERE	D 1/30/08	





JUN 0 5 2002

TECH CENTER 1600 2999 6 of 18

Form PTO-14 odified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Ž,

Docket No. **AREN-0320**

Serial No. 10/083,168

Applicant

Chen W. Liaw et al.

Filing Date

Group

February 26, 2002

ТО	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
Laue, L. et al., "Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty Proc. Natl. Acad. Sci USA, 1995, 92, 1906-1910						
C	CD Løvl isola	tie, R. et al., "The Ca ²⁺ -sensing receptor gene (PCAR1) mutation T151M in ted autosomal dominant hypoparathyroidism," <i>Hum. Genet</i> , 1996, 98, 129-133				
C	E Lefk	towitz, R. et al., "Constitutive activity of receptors coupled to guanine nucleotide latory proteins," <i>Trends Pharmacol. Sci.</i> , 1993, 14, 300-307				
C	rearr	rmann, T. et al., "Amplification, enhanced expression and possible rangement of EGF receptor gene in primary human brain tumours of glial in," <i>Nature</i> , 1985, 313, 144-147				
C	facto	Liu, C. et al., "Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas," Oncogene, 1992, 7, 181-185				
C	med	Liu, J. et al., "Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis," J. Biol. Chem., 1996, 271(11), 6172-6178				
C	kina	Lonardo, F. et al., "The normal <i>erbB-2</i> product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand," <i>New Biologist</i> , 1990 , 2(11), 992-1003				
C	CJ Mae	enhaut, C. et al., "RDC8 codes for an adenosine A2 receptor with physiological stitutive activity," <i>Biochem. Biophys. Res. Comm.</i> , 1990, 173(3), 1169-1178				
C	CK Mar	Mann, J. et al., "Increased serotonin ₂ and β-adrenergic receptor binding in the frontal cortices of suicide victims," Arch. Gen. Psychiatry, 1986, 43, 954-959				
	dete	Marone, R.L. et al., "Human CRF receptor chimeras: Mapping of ligand binding determinants," 26th Meeting of the Society of Neuroscience, Washington, D.C. November 16-21, 1996, Abstract No. 609.8				
N C	CM Mag	gnusson, Y. et al., "Autoimmunity in idiopathic dilated cardiomyopathy," culation, 1994, 89, 2760-2767				
EXAMINER	₹	DATE CONSIDERED (/30/80				





JUN 0 5 2002

TECH CENTER 1600/2900
Docket No. Serial No. 10/083,168

Form PTO diffied

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office Applicant Chen W. Liaw et al.

Filing Date Group February 26, 2002 1646

				and Trauemark Office
Γ			OTHE	R DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	N	ſß	CN	Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in <i>Xenopus</i> Oocytes and AtT20 Cells," <i>J. Biol. Chem.</i> , 1995, 270(3), 1041-1047
			CO	Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essential for kinase activity and macrophage colony-stimulating factor-dependent internalization," <i>Mol. Cell. Biol.</i> , 1994, 14(7), 4843-4854
1			CP	Nanevicz, T. et al., "Thrombin receptor activating mutations," J. Biol. Chem., 1996, 271(2), 702-706
			CQ	Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," <i>Br. J. Cancer</i> , 1993, 68, 746-750
			CR	Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome," J. Biol. Chem., 1995, 270(44), 26037-26040
	7.77		CS	Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-induced inhibition of aldosterone production in adrenal glomerulosa cells," J. Pharm. Exp. Ther., 1992, 263(1), 241-245
			СТ	O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human β2-adrenergic receptor," J. Biol. Chem., 1988, 263(31), 15985-15992
			CU	Offermanns, S. et al., "Ga ₁₅ and Ga ₁₆ Couple a Wide Variety of Receptors to Phospholipase C," J. Biol. Chem., 1995, 270, 15175-15180
			CV	Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," J. Med. Chem., 1994, 37, 4508-4521
			CW	Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," J. Biol. Chem., 1996, 271(14), 7949-7955
	V	/	СХ	Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism," J. Clin. Endocr. Metabl., 1996, 81, 3584-3588
	EXA	MIN	ER	DATE CONSIDERED 6/36/58

蹇



JUN 0 5 2002

TECH CENTER 1600/2900 Sheet 8 of 18

Form	PTO-14 Modified
------	-----------------

Edogudocket No. AREN-0320

Serial No. 10/083,168

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

Applicant Chen W. Liaw et al.

U.S. Department of Commerce Patent and Trademark Office

Filing Date February 26, 2002

Group 1646

		OTHE	CR DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	pm	CY	Parma, J. et al., "Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas," <i>Nature</i> , 1993, 365, 649-651			
		CZ	Pei, G. et al., "A constitutive active mutant β ₂ -adrenergic receptor is constitutively desensitized and phosphorylated," <i>Proc. Natl. Acad. Sci. USA</i> , 1994, 91, 2699-2702			
Pendley, C.E. et al., "The gastrin/cholecystokinin-B receptor antagonist L-36: basal acid secretion and prevents gastrointestinal damage induced by aspirin, et cysteamine in the rat," J. Pharmacol. Exp. Ther., 1993, 265(3), 1348-1354						
		DB	Peroutka, S., "Serotonin receptor subtypes. Their evolution and clinical relevance," CNS Drugs, 1995, 4 (Suppl. 1), 18-28			
DC Pettibone, D.J. et al., "Development and pharmacological assessment of novel pe and nonpeptide oxytocin antagonists," Regul. Pept., 1993, 45, 289-293						
	DD Prat, M.P. et al., "The receptor encoded by the human c-Met oncogene is expressed in hepatocytes, epithelial cells and solid tumors," Int. J. Cancer, 1991, 49, 323-328					
		DE	Prezeua, L. et al., "Changes in the carboxy-terminal domain of metabotropic glutamate receptor 1 by alternate splicing generate receptors with differing agonist-independent activity," <i>Mol. Pharmacol.</i> , 1996, 49, 422-429			
DF Rakovska, A. et al., "Effect of loxiglumide (CR 1505) on CCK-induced and ³ H-acetylcholine release from guinea-pig gallbaldder," <i>Neuropeptide</i> 25(5), 271-276						
		DG	Ren, Q. et al., "Constitutive active mutants of the α ₂ -adrenergic receptor," J. Biol. Chem., 1993, 268, 16483-16487			
		DH	Reynolds, E.E. et al., "Pharmacological characterization of PD 156707, an orally active ET _A receptor antagonist," <i>J. Pharmacol. Exp. Ther.</i> , 1995, 273(3), 1410-1417			
		DI	Robbins, L.S. et al., "Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function," Cell, 1993, 72, 827-834			
	V	DJ	Rong, S. et al., "Met expression and sarcoma tumorigenicity," Cancer, 1993, 53(22), 5355-5360			
F	EXAMINE	R	NING DATE CONSIDERED 6/30/08			

Section Section

JUN 0 5 2002 May 2.8 200 TECH CENTER 1600/2900 Sheet 9 of 18 Docket Nonage Serial No. Form PTO-1449 Modified **AREN-0320** 10/083,168 Applicant List of Patent and Publications Chen W. Liaw et al. Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Filing Date Group 1646 February 26, 2002 Patent and Trademark Office OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Samama, P. et al., "A mutation-induced activation state of the \(\beta 2\)-adrenergic NIA receptor," J. Biol. Chem., 1993, 268(7), 4625-4636 Sautel, M. et al., "Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an DL overlapping binding site at the human Y1 receptor," Am. Soc. Pharm. Exp. Ther., 1996, *50*, 285-292 Sawutz, D.G. et al., "Pharmacology and structure-activity relationships of the **DM** nonpeptide bradykinin receptor antagonist WIN 64338," Can. J. Physiol. Pharmacol., **1995,** *73,* 805-811 Scheer, A. et al., "Constitutively active G protein-coupled receptors: potential mechanisms DN of receptor activation," J. Rec. Signal Transduct. Res., 1997, 17(1-3), 57-73 Scheer, A. et al., "The activation process of the α_{1B} -adrenergic receptor: Potential role DO of protonation and hydrophobicity of a highly conserved aspartate," Proc. Natl. Acad. Sci. USA, 1997, 94, 808-813 Schwinn, D.A. et al., "Cloning and pharmacological characterization of human Alpha-DP 1 adrenergic receptors: sequence corrections and direct comparison with other species homologues," J. Pharmacol., 1995, 272(1), 134-142 Schild, L. et al., "A mutation in the epithelial sodium channel causing Liddle disease DQ increases channel activity in the Xenopus laevis oocyte expression system," Proc. Natl. Acad. Sci. USA, 1995, 92, 5699-5703 Seeman, P. et al., "Dopamine receptor pharmacology," Trends Pharmacol. Sci., 1994, DR

Seeman, P. et al., "Dopamine D4 receptors elevated in schizophrenia," Nature, 1993,

Sharif, M. et al., "Malignant transformation by G protein-coupled hormone receptors,"

DATE CONSIDERED

6/30/08

Serradeil-Le Gale, C. et al., "Biochemical and pharmacological properties of SR

49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V_{1a}

receptors," J. Clin. Invest., 1993, 92, 224-231

Mol. Cell. Endocrinology, 1994, 100, 115-119

3 . .

15, 264-270

365, 441-445

DS

DT

DU

EXAMINER

7

一 対方では

1.640.

COPY OF PAPERS ORIGINALLYEILED

ż

RECEIVED JUN 0.5 2002 ECH CENTER 1600/2900

Form PTO-1449 Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Docketayo AREN-0320

Serial No. 10/083,168

Applicant

Chen W. Liaw et al.

Filing Date February 26, 2002 Group 1646

		ОТНЕ	ER DOCUMENTS (Including Author	r, Title, Date, Pertinent Pages, Etc.)
	NM	DV		the erythropoietin receptor by the Friend spleen in induces constitutive protein tyrosine 2), 3070-3078
	1	DW	Skinner, R.H. et al., "Direct measure using scintillation proximity assay,"	ment of the binding of RAS to neurofibromin Anal. Biochem., 1994, 223, 259-265
		DX .	Slamon, D.J. et al., "Human breast c amplification of the HER-2/neu once	ancer: correlation of relapse and survival with ogene," Science, 1987, 235, 177-182
		DY	Slamon, D. et al., "Studies of the HE ovarian cancer," Science, 1989, 244,	R-2/neu proto-oncogene in human breast and 707-712
		DZ	Solomon, Y. et al., "A highly sensiti 1974, 58, 541-548	ve adenylate cyclase assay," Anal. Biochem.,
		EA	Spiegel, A.M., "Defects in G protein Ann. Rev. Physiol., 1995, 58, 143-17	-coupled signal transduction in human disease,"
		EB	binding site reveal different binding mo	tation studies on the histamine H ₁ -receptor agonist des for H ₁ -agonists: Asp ¹¹⁶ (TM3) has a constitutive ter-Aided Mol. Design, 1995, 9, 319-330
		EC		pendent activity is a distinguishing feature of the Biol. Chem., 1994, 269(45), 27925-27931
		ED		tivation of c-kit in FMA3 murine mastocytoma no acids at the juxtamembrane domain," Blood,
		EE	Wang, Z. et al., "Constitutive µ opiounderlying narcotic tolerance and de	d receptor activation as a regulatory mechanism pendence," <i>Life Sci.</i> , 1994 , <i>54(20)</i> , 339-350
	V	EF	Watowich, S.S. et al., "Homodimeriz erythropoietin receptor," <i>Proc. Natl.</i>	ation and constitutive activation of the Acad. Sci USA, 1992, 89, 2140-2144
E	XAMINE	R	Nom CR	DATE CONSIDERED 6/70/05
			V	

Chink ingelie

Š



COPY OF PAPEH. ORIGINALLY FILED

RECEIVED

JUN 0 5 2002

TECH CENTER 1600/2900 8 neet 11 of 18

	<u> </u>	<u>OA</u>	BAD		Sheet 11 of 18		
F	orm P	TO IS M	odified	Docket No. AREN-0320	Serial No. 10/083,168		
	Ci	Patent and Publi ited by Applican eral sheets if ne	nt	Applicant Chen W. Liaw et al.			
		partment of Cor and Trademark		Filing Date Group February 26, 2002 1646			
O	THER	DOCUMENT	S (Including Author	, Title, Date, Pertine	nt Pages, Etc.)		
NU		lymphoid and n		ntive activation of STAT proteins in primary Ils and in Epstein-Barr virus (EBV)-related			
	ЕН	Webster, M.K. transmembrane p	et al., "Constitutive act point mutation found in	ivation of fibroblast gro- achondroplasia," <i>EMBC</i>	wth factor receptor 3 by the 0 J., 1996, 15, 520-527		
				rmal growth factor receptor gene expression in malignant il. Acad. Sci. USA, 1984, 81, 7308-7312			
		the c-new/erbB2	transmembrane dom	f the insulin receptor transmembrane domain with domain constitutively activates the insulin receptor 92, 267(18), 12452-12461 Dynorphins as Endogenous Ligands for an Opioid J. Biol. Chem., 1995, 270, 22772-22778 actional domains critical for constitutive activation orgene, 1994, 9, 1691-1697			
	EK	Zhang, S. et al. Receptor-Like	, "Identification of Dy Orphan Receptor," <i>J. I</i>				
		Pauwles, P.J. et Activation of G 135	al., "Review: Amino -Protein-Coupled Rec	ino Acid Domains Involved in Constituve Receptors", <i>Molecular Neurobiology</i> , 1998 , 17, 109- ets and Neutral Antagonists of Recombinant Human expressed in Chinese Hamster Ovary Cells", 53, 886-893			
	1	A1 Adenosine					
				ntive Activiy of the Hum., 1998, 273, 24181-			
		•	et al., "Androstane Me β", <i>Nature</i> , 1998, 395		Deactivate the Nuclear		
V		mediated Signa		Gsβ Splice Variants of Chem., 1998, 273, 51	n β2-Adrenoreceptor- 109-5116		
EXAMINER	2	VIN	~	DATE CONSIDER	ED 6/30/66		





JUN 0 5 2002

	JF.	CH CENTER 1600/2500 12 of 18
Form Process Modified	Docket No. AREN-0320	Serial No. 10/083,168
List of Patent and Publications Cited by Applicant	Applicant Chen W. Liaw, e	t al.

(Use several sheets if necessary)

Filing Date
February 26, 2002 Group U.S. Department of Commerce Patent and Trademark Office 1646

	ОТНЕ	R DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
Na	ER	Abola, A.P., et al., "Omo sapiens chromosome 13 clone RP11-286P8, complete sequence," AC026756 XP-002175912, April 24, 2000, 1-41				
	ES	Adams, M.D., et al., "CIT-HSP-2286K19.TF CIT-HSP homo sapiens genomic clone 2286K19, genomic survey sequence," AQ001459, XP-002175783, August 24, 2001, 1 page				
	ET	Birren, B., et al., "Homo sapiens chromosome 11, clone RP11-589F4," AC027026, XP002175913, April 27, 2000, 1-40				
	EU	Birren, B., et al., "Homo sapiens clone RP11-15H8, 31 unordered pieces," AC011780, XP002175781, October 18, 1999, 1-46				
	EV	Birren, B., et al., "Homo sapiens clone RP11-14N15," AC016468, XP002175784, December 1, 1999, 1-38				
	EW	Boyer, J.L., et al., "Molecular cloning and expression of an avian G protein-coupled P2Y receptor," Am. Soc. For Pharmacology & Experimental Therapeutics, XP-002175907, 1997, 928-934				
	EX	Burton, J., et al., "Human DNA sequence from clone RP11-163L4," A1161458, XP002175911, April 16, 2000, 1-39				
	EY	Burton, J., "Human DNA sequence from clone RP11-15909," AL136106, XP002175785, January 7, 2000				
	EZ	Collier, R., "DJ68ON, 3 (G-protein coupled receptors) (fragment)," Accession Nr. Q9NTTO, XP002168498, January 10, 2001, 1 page				
V	FA	Doe Joint Genome Institute, "Homo sapiens chromosome 5 clone CTC-502M5, complete sequence," AC008547, XP002175786, August 4, 1999, 1-30				
EXAMINE	R	V 1 N DATE CONSIDERED 6/30/58				

この経済を行るとの





JUN 0 5 2002

TECH CENTER 1600/2900 Sheet 13 of 18

Form	PTO-1449 Modified	Docket No. AREN-0320	Serial No. 10/083,168	
	of Patent and Publications Cited by Applicant everal sheets if necessary)	Applicant Chen W. Liaw, et al		
	Department of Commerce nt and Trademark Office	Filing Date February 26, 2002	Group 1646	
ОТН	ER DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)	
pu FB	Doe Joint Genome Institute, "Homo complete sequence," AC008754, XP	sapiens chomosome 19 002175778, August 4,	clone CTD-3023J11, 1999, 1-18	
FC Doe Joint Genome Institute, "Sequencing of human chromosome 5," AC00 XP002175776, August 4, 1999, 1-42		some 5," AC008728,		
FD Gempscpue, "Drosophila melanogaster genome survey sequence TET3 end of BACRO8K10 of RPCI-98 library from drosophila melanogaster (fruit fly)," AL065769, XP00217590				
FE	Hattori, M., et al., "Homo sapiens 17 XP002175780, December 3, 1999, 1-	1, 539 genomic of 11q 45	13," AP000808,	
FF	FF Heise, C.E., et al., "Characterization of the human cysteinyl leukotriene 2 receptor, Biological Chemistry, September 29, 2000, 275(39), 30531-30536			
FG Kjelsberg, M.A., et al., "constitutive activation of the α _{1B} - adrenergic receptor by amino acid substitutions at a single site," J. Biological Chemistry, XP-00213576 1992, 265(3), 1430-1433				
FH	Mahairas, G.G., et al., "Sequence-tag mapping and scanning the human ger 96, 9739-9744	ged connectors: A sequence," Proc. Natl. Acad	nence approach to d. Sci. USA, August 1999,	
FI	Marchese, A., et al., "Novel GPCRs a boundaries of physiology and pharma	and their endogenous li acology," <i>TiPS</i> , Septem	gands: expanding the ber 1999, 20, 370-375	
FJ	O'Dowd, B.F., et al., "Discovery of the Genomics, XP-000863786, 1998, 310	nree novel G-protein-co	oupled receptor genes,"	
FK	Ohono, M., et al., "Homo spiens mRi complete cds," AB038237, XP00217			
∀ FL	Stadel, J.M., et al., "Orphan G protein pioneer drug discovery," <i>TiPS</i> , Nover			
EXAMINER	Vimph	DATE CONSIDERE	CD 6/3 o/or	

COPY OF PAPERS

Ġ





JUN 0 5 2002 TECH CENTER 1600/2900

Sheet 14 of 18

		- B	HAD		Sheet 14 of 18	
		Form	1449 Modified	Docket No. AREN-0320	Serial No. 10/083,168	
			Cited by Applicant	Applicant Chen W. Liaw, et al	•	
	List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office Filing Date February 26, 2002 FM Stone, N., et al., "Homo sapiens chomosome 4, 16 unordered pieces," AC007104, XP002175914, April 23, 1999, 1-52 FN Wallis, J., "Human DNA sequence from clone RP5-1160K1," AL355310, XP002175782, May 5, 2000, 1-39 FO Waterson, R.H., "homo sapiens chromosome 2 clone RP11-510c1," AC010984, XP002175915, September 29, 1999, 1-50 FP Weinshank, R.H., "5-hydroxytryptamine 1B receptor (-HT-1B) (serotonin receptor)," AC 008892, XP002175948, July 15, 1998, 1 page FQ Zhao, S., et al., "Use of BAC end sequences from library RPCI-11 for sequence-ready map building," AQ532303, XP002175779, May 18, 1999, 1 page FR PCT International Search Report dated September 19, 2001 FS Watson, S. et al., "The G-Protein linked receptor facts book", Academic Press, 2-6, 162-169					
		OTHE	ER DOCUMENTS (Including Author	r, Title, Date, Pertine	nt Pages, Etc.)	
NL	_	FM	Stone, N., et al., "Homo sapiens chon XP002175914, April 23, 1999, 1-52	nosome 4, 16 unordere	d pieces," AC007104,	
		FN	Wallis, J., "Human DNA sequence from XP002175782, May 5, 2000, 1-39	om clone RP5-1160K1	," AL355310,	
	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				510c1," AC010984,	
		FP	Weinshank, R.H., "5-hydroxytryptam AC 008892, XP002175948, July 15, 1	ine 1B receptor (-HT-1998, 1 page	B) (serotonin receptor),"	
		FQ	Zhao, S., et al., "Use of BAC end sequence map building," AQ532303, XP00217	uences from library RF 5779, May 18, 1999, 1	CI-11 for sequence-ready page	
·		FR	PCT International Search Report date	d September 19, 2001		
		FS	Watson, S. et al., "The G-Protein link 162-169	ed receptor facts book'	, Academic Press, 2-6,	
1	/	FT	Rudinger, J. et al., Peptide Hormones, 1-7	J.A. Parsons, Unovers	sity Park Press, Baltimore,	
V				· · · · · · · · · · · · · · · · · · ·		

DATE CONSIDERED

6/30/00

423

EXAMINER

Assistant.

ź

RECEIVED JUN 0.5 2002

	- A	AND A	y 	JUN 0 5 ZOUZ Sheet 15 of 18		
	Fort	BTO 449 Modified	Docket No. AREN-0040 Applicant Liaw, et al.			
		of Patent and Publications Cited by Applicant several sheets if necessary)				
	U.S. I	Department of Commerce nt and Trademark Office	Filing Date Group October 13, 1998 1646			
	ОТН	ER DOCUMENTS (Including Autho	r, Title, Date, Pertine	nt Pages, Etc.)		
pr	FU	Bergsma, D.J., et al., "Cloning and creceptor," Biochem. & Biophy. Res. (characterization of a huccomm., 1992, XP-0021	man angiotensin II type 1 45165, 183(3), 989-995		
	FV	Gantz, I., et al., "Molecular cloning, of melanocortin receptor," J. Biol. Chem.	expression, and gene localization of a fourth em., 1993, XP-002051983, 268(20), 15174-15178			
	FW	Groblewski, T., et al., "Mutation of A AT _{1a} angiotensin II receptor induces in XP-002145162, 272(3), 1822-1826	on 111 in the third transmembrane domain of the s constitutive activation, "J. Biol. Chem., 1997,			
	FX	Koike, G., et al., "Human type 2 angi X chromosome, and its mRNA is exp Biophy. Res. Comm., 1994, XP-00214	piotensin II receptor gene: cloned, mapped to the pressed in the human lung," <i>Biochem. And</i> 45166, 203(3), 1842-1850			
	FY	zation, and mapping of DNA and Cell Biology	human homolog of , 1998, XP000929737,			
	FZ	Noda, K., et al., "The active state of the angiotensin II induction," Biochem., 1	ne AT ₁ angiotensin reco 996, XP-002145163, 3	eptor is generated by 35, 16435-16442		
	GA	Reppert, S.M., et al., "Cloning of a m FEBS Letts., 1996, XP-002145161, 2	elatonin-related receptor	or from human pituitary,"		
\bigvee	GB	Scheer, A., et al., "Constitutively active mechanisms of receptor activation," J. XP-000867531, 17(1-3), 57-73	ve G protein-coupled re Receptor & Signal Tr	exceptors: potential ansduction Res., 1997,		
		Non				
EXAMIN	ER	Vrgm	DATE CONSIDERE	D 4/30/00		

COPY OF PAPERS ORIGINALLY FILED

arth.

an Authorities

Ŗ

1000



MI 2 9 202

RECEIVED

JUN 0 5 2002

TECH CENTER 1600/2900 Sheet 16 of 18

Form PTO-144 Whodified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

BEKET No.	
AREN-0320	

Serial No. 10/083,168

Applicant

Chen W. Liaw, et al.

Filing Date February 26, 2002

Group 1646

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
N	GC	5,861,309	01/19/99	Bard, et al.	135	325
	GD	5,891,720	04/06/99	Moore, et al.	435	325
	GE	5,955,308	09/21/99	Bergsma, et al.	435	69.1

FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation YES NO
per	GF	WO 96/05302	02/22/96	PCT	
	GG	WO 97/21731	06/19/97	PCT	
	GH	WO 98/29439	07/09/98	PCT	
	GI	WO 98/46620	10/22/98	PCT	
	GJ	WO 98/56820	12/17/98	PCT	
	GK	WO 99/06552	02/11/99	PCT	
	GL	WO 99/32519	07/01/99	PCT	
	GM	WO 99/48921	09/30/99	PCT	
	GN	WO 00/14229	03/16/00	PCT	X (abstract)
	GO	WO 00/22131	04/20/00	PCT	
	GP	WO 00/49046	08/24/00	PCT	X (abstract)
	GQ	WO 01/07606 A1	02/01/01	PCT	
	GR	WO 01/09184 A1	02/08/01	PCT	
	GS	WO 01/12673 A1	02/22/01	PCT	
EXAMINE	R	Win	_	DATE CONSII	DERED 6/30/0~

COPY OF PAPERS

.

7

1.00

ij

WILDAY E

MN 29 202 2

RECEIVED

JUN 0 5 2002

TECH CENTER 1600/8900

Form PTO-1449 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office RATE DECKET No. AREN-0320

Serial No. 10/083,168

Applicant

Chen W. Liaw, et al.

Filing Date

Group

February 26, 2002 1646

FOREIGN	PATENT	DOCUMENTS
---------	--------	------------------

		T	GNIAIENI	T		
Examiner Initial		Document No.	Date	Country	1	nslation NO
Nr	GT	WO 01/14577 A1	03/01/01	PCT		
1	GU	WO 01/16159 A1	03/08/01	PCT	 -	
	GV	WO 01/31014 A2	05/03/01	PCT		
	GW	WO 01/36471 A2	05/25/01	PCT		
	GX	0 612 845 A2	08/31/94	EPO		
	GY	0 878 542 A2	11/18/98	EPO		
	GZ	0 892 051 A2	01/20/99	EPO		-
	НА	1 090 989 A1	04/11/01	EPO		
V	нв	1 094 076 A1	04/25/01	EPO		
	не	8-245697	09/24/99	Japan		X
	HD_	11-32770	02/09/99	Japan		х
1	HE	11-98988	09/13/99	Japan	X (abstract)	
<u>'</u>						
EXAMINER	1	1-5n		DATE CONSIDER	ED 6/30	do

ORIGINALE PRIED

. .

...

18841...

Marz 8 44 85

NN 19 TOR B

RECEIVED

JUN 0 5 2002 TECH CENT<u>&R=1608/29018</u>

Form PTO 1450 Modified

List of Patent and Publications
Cited by Applicant
(Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office AREN-0320

Serial No. 10/083,168

Applicant

Chen W. Liaw et al.

Filing Date February 26, 2002

Group 1646

U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
\mathcal{M}	HF	5,514,578	05/07/96	Hogness et al.	435	240.2
_ ' \	HG	5,532,157	07/02/96	Fink	435	240.2
	НН	5,573,944	11/12/96	Kirschner et al.	435	252.3
	HI	5,639,616	06/17/97	Liao et al.	435	7.1
	HJ	5,750,353	05/12/98	Kopin et al.	435	7.21
		<u> </u>				

FOREIGN PATENT DOCUMENTS

Examiner nitial		Document No.	Date	Country	Translation YES NO
ph	HK	WO 97/11159	09/20/96	PCT	x
1_	HL	WO 97/21731 A	06/19/97	PCT	X
	НМ	WO 98/38217 A	09/03/98	PCT	X
	HN	WO 98/46995	10/22/98	PCT	X
	но	WO 99/52927	10/21/99	PCT	X
	HP	WO 98/00552	01/08/98	PCT	X
	НQ	WO 98/34948	08/13/98	PCT	X
	HR	WO/99 24569	05/20/99	Japan	X
1	HS	2,135,253	08/05/96	Canada	X
XAMINEI	S V	ートル	<u> </u>	DATE CONSII	

ORIGINALLY FILES

4

-Profes

1,5%